T cell receptors (TCRs) allow T cells to interact with other immune cells and identify and target cancer cells. Upon activation, these TCRs can form giant clusters with other proteins in T cells. The effects of this clustering are unknown though, so Dr. Su established a system that models the TCR signaling pathway to investigate them. He’s found that the clusters enhance the activity of certain enzymes, which promote both T cell activation and T cells’ interactions with tumor cells. These insights may lead to the development of therapies that trigger these clusters to improve the anti-tumor ability of T cells.
University of California, San Francisco | All Cancers, Leukemia | 2014 | Ronald D. Vale, Ph.D.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
This July for Sarcoma Awareness Month, we look at new research, new treatments, and how we’re working toward a future immune to sarcoma.
CRI-Chordoma Foundation CLIP Investigator Dr. Cassian Yee is exploring how to design cell therapies for patients with a rare type of sarcoma.